GoodRx (NASDAQ:GDRX) Stock Price Up 8.7% – Time to Buy?

GoodRx Holdings, Inc. (NASDAQ:GDRX) shares rose 8.7% on Friday . The company traded as high as $2.54 and last traded at $2.5650. Approximately 1,919,610 shares traded hands during trading, a decline of 26% from the average daily volume of 2,605,224 shares. The stock had previously closed at $2.36.

Wall Street Analysts Forecast Growth

A number of research analysts recently weighed in on the stock. The Goldman Sachs Group dropped their price objective on shares of GoodRx from $4.00 to $2.50 and set a “neutral” rating for the company in a report on Monday, March 2nd. Citigroup dropped their price objective on shares of GoodRx from $4.50 to $3.50 and set a “buy” rating for the company in a report on Tuesday, March 3rd. JPMorgan Chase & Co. restated a “neutral” rating on shares of GoodRx in a report on Friday, February 27th. Mizuho dropped their price objective on shares of GoodRx from $4.00 to $3.00 and set a “neutral” rating for the company in a report on Friday, February 27th. Finally, Wall Street Zen cut shares of GoodRx from a “buy” rating to a “hold” rating in a report on Sunday, January 25th. Five analysts have rated the stock with a Buy rating, seven have given a Hold rating and three have given a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $3.85.

GoodRx Stock Up 8.1%

The business’s fifty day moving average is $2.19 and its two-hundred day moving average is $2.62. The company has a quick ratio of 2.61, a current ratio of 2.61 and a debt-to-equity ratio of 0.78. The stock has a market cap of $873.55 million, a price-to-earnings ratio of 28.34, a PEG ratio of 1.76 and a beta of 1.54.

GoodRx (NASDAQ:GDRX) last posted its quarterly earnings results on Wednesday, February 25th. The company reported $0.09 EPS for the quarter, hitting the consensus estimate of $0.09. GoodRx had a net margin of 3.82% and a return on equity of 9.31%. The company had revenue of $194.79 million during the quarter, compared to analysts’ expectations of $193.27 million. During the same quarter in the previous year, the business posted $0.09 EPS. The firm’s revenue was down 1.9% on a year-over-year basis. Equities analysts forecast that GoodRx Holdings, Inc. will post 0.15 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. LSV Asset Management grew its holdings in GoodRx by 517.1% during the 3rd quarter. LSV Asset Management now owns 2,354,581 shares of the company’s stock worth $9,960,000 after acquiring an additional 1,973,017 shares in the last quarter. Universal Beteiligungs und Servicegesellschaft mbH acquired a new position in GoodRx during the 3rd quarter worth approximately $3,036,000. Pathway Capital Management LP grew its holdings in GoodRx by 69.0% during the 3rd quarter. Pathway Capital Management LP now owns 986,158 shares of the company’s stock worth $4,171,000 after acquiring an additional 402,721 shares in the last quarter. Versor Investments LP acquired a new position in GoodRx during the 3rd quarter worth approximately $155,000. Finally, Teacher Retirement System of Texas grew its holdings in GoodRx by 40.4% during the 3rd quarter. Teacher Retirement System of Texas now owns 138,130 shares of the company’s stock worth $584,000 after acquiring an additional 39,759 shares in the last quarter. Institutional investors and hedge funds own 63.77% of the company’s stock.

About GoodRx

GoodRx Holdings, Inc (NASDAQ: GDRX) operates a digital healthcare platform designed to help consumers compare prescription drug prices at retail pharmacies across the United States. Through its website and mobile applications, GoodRx aggregates pricing and discount information from a wide network of pharmacies, enabling users to access coupons and savings programs on both generic and brand-name medications. The platform also features price transparency tools that inform patients about cost variations and available discounts to alleviate the financial burden of prescription medications.

In addition to its core drug pricing service, GoodRx offers telehealth services under the GoodRx Care brand, providing virtual consultations for a range of non-emergency conditions and prescription needs.